TherapeuticsMD (TXMD) Cash from Operations (2010 - 2026)

TherapeuticsMD has reported Cash from Operations for 17 years, with the latest figure at 944000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 35.05% year-over-year to 944000.0; the trailing twelve-month figure through Mar 2026 stood at 2699000.0 (up 28.65% YoY), and the FY2025 full-year result was 2454000.0, up 109.74% from the prior year.
• Cash from Operations for Q1 2026 stood at 944000.0, up from 375000.0 in the prior quarter.
• The five-year high for Cash from Operations was 30236000.0 in Q4 2022, with the low at 20721000.0 in Q2 2022.
• Historically, Cash from Operations has averaged 538470.59 across 5 years, with a median of 17000.0 in 2024.
• Annual changes were most pronounced in 2023 — Cash from Operations tumbled 134.03% — and 2025, when it surged 2105.88%.
• TherapeuticsMD's Cash from Operations stood at 30236000.0 in 2022, then slumped by 116.4% to 4960000.0 in 2023, then jumped by 100.34% to 17000.0 in 2024, then surged by 2105.88% to 375000.0 in 2025, then jumped by 151.73% to 944000.0 in 2026.
• The last three Cash from Operations figures came in at 944000.0 (Q1 2026), 375000.0 (Q4 2025), and 999000.0 (Q3 2025), per Business Quant data.